Rifamycin sodium CR is under clinical development by Cosmo Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rifamycin sodium CR’s likelihood of approval (LoA) and phase transition for Diverticulitis took place on 29 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rifamycin sodium CR Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rifamycin sodium CR overview

Rifamycin sodium (Aemcolo, Relafalk) is an anti-infective agent. It is formulated as controlled release film coated tablets, tablets for oral route of administration.Aemcolo is indicated for the treatment of adult patients with travelers diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

Rifamycin SV MMX is under development for the treatment of diarrhoea predominant irritable bowel syndrome (IBS-D), uncomplicated diverticulitis, minimal hepatic encephalopathy and small intestine bacterial overgrowth (SIBO) and travelers diarrhea in adolescents of 12 to 17 years. It was also under development for the treatment of infectious colitis, and infectious diarrhea.

Cosmo Pharmaceuticals overview

Cosmo Pharmaceuticals (Cosmo) is a pharmaceutical company. The company develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company offer products such as Lialda, Mezavant, Mesavancol, and Uceris for the treatment of ulcerative colitis It also offers Eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. Its manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.

Quick View Rifamycin sodium CR LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Rifamycin sodium CR
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
Key Developers
Highest Development Stage
  • Marketed

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.